Role of palliative care in adolescent and young adult oncology
S Wein, S Pery, A Zer - Journal of clinical oncology, 2010 - ascopubs.org
Adolescents and young adults (AYAs) with cancer are a heterogeneous group. Nevertheless,
there are sufficient unifying characteristics to form a distinct clinical entity. Management of …
there are sufficient unifying characteristics to form a distinct clinical entity. Management of …
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non …
…, D Daniel, S McCune, T Mekhail, A Zer… - The Lancet …, 2019 - thelancet.com
Background Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer
immunity, improved overall survival in patients with previously treated non-small-cell lung …
immunity, improved overall survival in patients with previously treated non-small-cell lung …
Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer
…, A Stemmer, A Levy-Barda, S Yust-Katz, A Zer… - JAMA …, 2021 - jamanetwork.com
Importance Patients with cancer undergoing treatment are at high risk of COVID-19 following
SARS-CoV-2 infection; however, their ability to produce an adequate antibody response to …
SARS-CoV-2 infection; however, their ability to produce an adequate antibody response to …
[HTML][HTML] Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 …
…, B Gao, D Planchard, M Gottfried, A Zer… - Journal of Thoracic …, 2020 - Elsevier
Introduction Pembrolizumab has shown clinical benefit in patients with previously treated
recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 (NCT02054806 …
recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 (NCT02054806 …
Hospitalisations and emergency department visits in cancer patients receiving systemic therapy: Systematic review and meta‐analysis
RM Prince, M Powis, A Zer, EG Atenafu… - European journal of …, 2019 - Wiley Online Library
Emergency department visits and hospitalisations (ED+H) during systemic therapy are
undesirable for both patients and the health system. We undertook a systematic literature review …
undesirable for both patients and the health system. We undertook a systematic literature review …
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
…, W Ros, B Gao, A Marabelle, M Gottfried, A Zer… - 2018 - ascopubs.org
8506 Background: The antitumor activity of pembrolizumab, an IgG4 anti-PD-1 monoclonal
antibody, was evaluated in patients (pts) with SCLC in KEYNOTE-158 (NCT02628067), a …
antibody, was evaluated in patients (pts) with SCLC in KEYNOTE-158 (NCT02628067), a …
[HTML][HTML] BRAF mutant lung cancer: programmed death ligand 1 expression, tumor mutational burden, microsatellite instability status, and response to immune check …
…, N Popovits-Hadari, D Urban, M Mishaeli, A Zer… - Journal of Thoracic …, 2018 - Elsevier
Introduction The efficacy of immune checkpoint inhibitors (ICPi) in BRAF mutant NSCLC is
unknown. Methods Multi-institutional retrospective chart review identified 39 patients with …
unknown. Methods Multi-institutional retrospective chart review identified 39 patients with …
Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma
MM Gounder, A Zer, WD Tap, S Salah… - Journal of Clinical …, 2016 - ascopubs.org
Purpose We evaluated the pharmacokinetics (PKs), pharmacodynamics, safety, and
efficacy of selinexor, an oral selective inhibitor of nuclear export compound, in patients with …
efficacy of selinexor, an oral selective inhibitor of nuclear export compound, in patients with …
Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases
…, S Yust-Katz, H Nechushtan, DA Goldstein, A Zer… - Lung Cancer, 2016 - Elsevier
Central nervous system (CNS) metastases occur in 30% of patients with advanced non-small
cell lung cancer (NSCLC). Localized treatments targeting CNS metastases result in delays …
cell lung cancer (NSCLC). Localized treatments targeting CNS metastases result in delays …
Evolution of randomized trials in advanced/metastatic soft tissue sarcoma: end point selection, surrogacy, and quality of reporting
A Zer, RM Prince, E Amir… - Journal of Clinical …, 2016 - ascopubs.org
Purpose Randomized controlled trials (RCTs) in soft tissue sarcoma (STS) have used varying
end points. The surrogacy of intermediate end points, such as progression-free survival (…
end points. The surrogacy of intermediate end points, such as progression-free survival (…